Analysts’ Opinions Are Mixed on These Healthcare Stocks: Evolent Health (EVH), Medtronic (MDT) and Cytokinetics (CYTK)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Evolent Health (EVH – Research Report), Medtronic (MDT – Research Report) and Cytokinetics (CYTK – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Evolent Health (EVH)
Truist Financial analyst Jailendra Singh maintained a Buy rating on Evolent Health today. The company’s shares closed last Tuesday at $2.56.
According to TipRanks.com, Singh ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolent Health with a $5.75 average price target, representing a 107.6% upside. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $4.00 price target.
See the top stocks recommended by analysts >>
Medtronic (MDT)
Truist Financial analyst Richard Newitter maintained a Hold rating on Medtronic today. The company’s shares closed last Tuesday at $96.75.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medtronic with a $113.64 average price target, which is a 15.3% upside from current levels. In a report issued on February 17, TipRanks – xAI also downgraded the stock to Hold with a $107.00 price target.
Cytokinetics (CYTK)
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Cytokinetics. The company’s shares closed last Tuesday at $70.10, close to its 52-week high of $75.71.
According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of
Currently, the analyst consensus on Cytokinetics is a Strong Buy with an average price target of $93.08, representing a 36.0% upside. In a report issued on February 19, Barclays also maintained a Buy rating on the stock with a $87.00 price target.
